Municipal Employees Retirement System of Michigan decreased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 24.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,140 shares of the biotechnology company’s stock after selling 4,250 shares during the quarter. Municipal Employees Retirement System of Michigan’s holdings in United Therapeutics Corporation were worth $1,540,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in United Therapeutics Corporation during the 3rd quarter valued at $156,000. Eagle Global Advisors LLC acquired a new stake in United Therapeutics Corporation during the 2nd quarter valued at $206,000. TLP Group LLC acquired a new stake in United Therapeutics Corporation during the 2nd quarter valued at $246,000. HPM Partners LLC lifted its holdings in United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the last quarter. Finally, Fort L.P. lifted its holdings in United Therapeutics Corporation by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 99 shares during the last quarter.

United Therapeutics Corporation (UTHR) opened at $123.02 on Friday. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89. The company has a market capitalization of $5,320.00, a price-to-earnings ratio of 10.46 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The company had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter last year, the business earned $4.23 earnings per share. United Therapeutics Corporation’s revenue was up 9.1% on a year-over-year basis. equities analysts forecast that United Therapeutics Corporation will post 11.92 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on the company. TheStreet downgraded United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, October 26th. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine upgraded United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Finally, Cowen and Company reiterated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics Corporation in a research report on Friday, October 27th. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and a consensus target price of $132.82.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Stake Lowered by Municipal Employees Retirement System of Michigan” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/18/united-therapeutics-corporation-uthr-stake-lowered-by-municipal-employees-retirement-system-of-michigan.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 7,061 shares of United Therapeutics Corporation stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $121.12, for a total value of $855,228.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,238 shares of United Therapeutics Corporation stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $130.65, for a total value of $161,744.70. Following the completion of the transaction, the chief executive officer now owns 2,307 shares in the company, valued at approximately $301,409.55. The disclosure for this sale can be found here. Insiders sold 23,879 shares of company stock worth $2,926,931 in the last 90 days. 7.80% of the stock is owned by company insiders.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.